To identify tumor antigens for glioma, a human testis cDNA library was screened by serological identification of antigens by recombinant expression cloning with sera from glioma patients. In this screening, the most frequently isolated antigen was SOX6, an Sry-related high-mobility group (HMG) box-containing gene. SOX6 is a transcriptional factor that is specifically expressed in the developing central nervous system and in the early stages of chondrogenesis in mouse embryos. IgG antibodies against SOX6 were detected in sera from 12 of 36 glioma patients (33.3%), 0 of 14 patients with other brain disease (0%), and one of 54 other cancer patients (1.9%). In sera from 37 healthy individuals, no IgG responses against SOX6 were detected, except in an elderly female. Furthermore, Western blot and ELISA analyses with sera from glioma patients revealed that the DNA-binding domain, the HMG box of SOX6, might be a dominant epitope of IgGs against SOX6. RT-PCR and Northern blot analysis revealed that the SOX6 gene was more highly expressed in glioma tissues than in normal adult tissues, except testis. Western blot analysis with an anti-SOX6 antibody demonstrated that the SOX6 protein was expressed in glioma tissues, but not in normal adult brain tissue. Immunohistochemical analysis with the anti-SOX6 antibody showed that all the glioma tissues analysed expressed SOX6 in tumor cells, but only a few SOX6-positive cells were detected in non-neoplastic tissues from the cerebral cortex. In summary, these results indicate
Introduction
Human malignant gliomas are rapidly progressing brain tumors of unknown etiology. Despite aggressive multimodal therapy, the prognosis for patients with malignant glioma is still poor. The current treatment of malignant gliomas, which consists of surgical resection followed by radiation therapy and/or chemotherapy, results in a median survival of less than 1 year (Prados and Philips, 1992) . Thus, the development of new therapeutic strategies is required.
The recent discovery of tumor antigens has opened new doors for specific tumor-targeted treatments using passive or active immunotherapeutic strategies. In particular, cancer/testis (CT) antigens, which are expressed in a variety of human cancers but not in normal tissues except for the testis, represent promising targets for immunotherapeutic and gene therapeutic approaches (Chen et al., 1997) . The expression analysis of seven CT antigens (MAGE-3, NY-ESO-1, HOM-MEL-40/SSX-2, SSX-1, SSX-4, HOM-TES-14/ SCP-1, and HOM-TES-85) showed that 60% of astrocytomas expressed at least one CT antigen (Sahin et al., 2000) , indicating that the majority of gliomas may be good targets for specific immunotherapy using CT antigens.
A recently developed strategy, serological identification of antigens by recombinant expression cloning (SEREX), has aided in the discovery of numerous new tumor antigens (Sahin et al., 1995; Old and Chen, 1998) . Several SEREX-defined antigens, including MAGE, tyrosinase, and NY-ESO-1, were originally detected with cytotoxic T cells (CTLs) (van der Bruggen et al., 1991; Brichard et al., 1993; Robbins et al., 1994) , and SEREX can isolate antigens recognized by both B and T cells; thus, it can be used to identify antigenic targets. The present study was designed to identify tumor antigens for human glioma by SEREX, using a testis cDNA library and allogenic glioma patients' sera. In this screening, the most frequently isolated antigen was a transcription regulator, SOX6, and we then further analysed its expression and immunoreactivity in human glioma.
Results
Isolation of immunoreactive clones recognized by IgG antibodies in glioma patient sera using SEREX Approximately 1 Â 10 6 clones from a human testis cDNA library were screened by SEREX using the mixed sera of four glioma patients (a 41-year-old male with anaplastic astrocytoma, 21-year-old female with glioblastoma, 7-year-old female with diffuse astrocytoma, and 3-year-old female with diffuse astrocytoma). In this screening, 11 clones encoding four gene products were isolated (data not shown). The most frequently isolated gene was SOX6, an Sry-related HMG boxcontaining gene, encoded by six of the 11 clones (55%). Moreover, the SOX6-encoding clones showed strong immunoreactivity with the glioma patient sera. Thus, SOX6 was further analysed for its immunogenicity and expression. Sequence analysis of the isolated SOX6 cDNA clones revealed that two different cDNA lengths were present. The longer clone (one of the six SOX6 cDNAs) contained the full-length SOX6 cDNA sequence of 3.5 kb (787 amino acids). The shorter clones (five of the six SOX6 cDNAs) contained approximately 1.8 kb from the 3 0 terminal end of the SOX6 cDNA (461 amino acids corresponding to residues 1040-2422). No mutation was detected among these SOX6 clones.
Analysis of IgG antibodies against SOX6 in sera from healthy individuals and patients with glioma and various cancers by SEREX To examine the relationship between the antibody response against SOX6 and glioma, serum screening of various patients and healthy individuals was performed. Sera from 36 patients with glioma (3-77 years old, average 43.8 years, 18 male and 18 female), 14 with other brain diseases (including meningioma, malignant lymphoma, metastatic brain tumor, Parkinson's disease, craniophalyngioma, central neurocytoma, brain abscess, and subarachnoid hemorrhage), 54 with various cancers, and 37 healthy individuals (20-83 years old, average 52.3 years, 20 male and 17 female) were diluted 1 : 100 and used to screen IgG antibodies to the SOX6 antigen, which was expressed by lambda phage-infected Escherichia coli, on a nitrocellulose membrane. Serological responses against SOX6 were observed in samples from 12/36 (33.3%) glioma patients, whereas in 0/14 (0%) samples from patients with other brain diseases, including inflammatory diseases, and 1/54 (1.9%) samples from patients with other cancers. In the sera from 37 normal adults, no IgG antibody against SOX6 was detected except in the sample from one elderly female (Table 1) . Most of these SOX6-positive sera from glioma patients also showed the positive reaction in 1 : 1000 dilution (data not shown), suggesting that hightiter IgG antibodies against SOX6 were present in glioma patients' sera. Regarding the serological responses in different WHO grade of gliomas, IgG antibodies of SOX6 were detected in seven of 19 (36.8%) patients with WHO grade IV gliomas, in four of 14 (28.6%) patients with grade III gliomas, and in one of three (33.3%) patients with WHO grade II gliomas. These results suggest that there is no apparent correlation between the immunogenicity of SOX6 and grade of malignancy in gliomas.
Moreover, sera that reacted with the clone encoding the full-length SOX6 cDNA also reacted with the shorter SOX6 clone (data not shown), suggesting that the IgG antibodies in glioma patients' sera recognized epitopes within the 461 amino-acid sequence located in the carboxyl-terminal region of SOX6 (residues 326-787), which includes the SOX6-HMG.
Analysis of the immunogenic epitope of SOX6
As SOX6-HMG, the DNA-binding site of SOX6, might have been recognized by the IgG antibodies in the glioma patients' sera, we prepared a His-tagged recombinant SOX6-HMG protein. Western blot analysis revealed that sera from the glioma patients who had positive seroreactivity against SOX6 also reacted with SOX6-HMG (Figure 1) . To measure the titer of antibody specific for this predicted immunogenic epitope, we further evaluated the serologic reactivity to SOX6-HMG by ELISA for the 12 patients with positive seroreactivity against SOX6 by SEREX. A significant difference in the seroreactivity to SOX6-HMG was observed between healthy individuals and glioma patients (Po0.05, unpaired t-test) (Figure 2 ). These results suggest that SOX6-HMG may be an immunogenic epitope recognized by IgG antibodies in sera from glioma patients.
Analysis of SOX6 gene expression in glioma
To evaluate the expression of the SOX6 gene in glioma and normal adult tissues, we performed an RT-PCR analysis. The SOX6 gene was highly expressed in gliomas and the testis, and faintly expressed in the brain, kidney, and muscle, but was not detectable in other adult tissues (Figure 3a) . We evaluated the difference in SOX6 gene expression between gliomas and the normal adult brain by quantitative RT-PCR analysis using SYBR Green. The SOX6 gene showed significantly higher expression in all the glioma tissues analysed than in the normal adult brain (Figure 3b) .
The large and small transcripts of SOX6 have been reported in mouse (Lefebvre et al., 1998; Hagiwara et al., 2000) and human (Cohen-Barak et al., 2001) , and the size difference is most likely owing to the different sizes of the 3 0 and 5 0 untranslated regions (UTRs) (Lefebvre et al., 1998) . The small transcript is predominantly expressed in the adult mouse testis and the large one is expressed in the developing mouse brain and mouse chondrocytes, but the expression significantly decreases in these adult tissues (Connor et al., 1995; Lefebvre et al., 1998) . To investigate which transcript is expressed in glioma, the expression of the SOX6 gene in human glioma was examined by Northern blot analysis. As shown in previous reports, two transcripts were detected: the large SOX6 transcript (8-9 kb) was detected in the human fetal brain; but not the adult brain, and the small transcript (3 kb) was detected in the testis (Figure 4 ). In human glioma tissues, the large SOX6 transcript was detected. In summary, the large transcript of SOX6 was expressed in the developing central neurons-system (CNS) and gliomas, in contrast to the expression of the small transcript, which was expressed predominantly in the testis.
Preferential expression of the SOX6 protein in glioma
The expression of the SOX6 protein in human glioma was evaluated by Western blot analysis with an anti-SOX6 polyclonal antibody. This antibody detected a 90-kDa band of the SOX6 protein in 293T cells transfected with the full-length SOX6 cDNA, but not in untransfected 293T cells (Figure 5a ). In this study, the SOX6 protein was expressed in gliomas, but not in normal adult brain tissue, in agreement with the results obtained by RT-PCR and the Northern blot analysis. To confirm the specificity of the anti-SOX6 antibody used and the SOX6 protein expression in gliomas, we also performed a Western blot analysis after neutralizing the antibody with recombinant SOX6 protein. The Figure 2 ELISA analysis of sera from 12 glioma patients, who had positive seroreactivity against SOX6, and healthy individuals against SOX6-HMG. There was a significant difference in the seroreactivity to SOX6-HMG between glioma patients and healthy individuals (Po0.05, unpaired t-test). Horizontal bars indicate median values 90-kDa bands in the 293T cells transfected with the SOX6 gene and glioma tissues disappeared in this blocking experiment (Figure 5b ), indicating that the antibody used specifically recognized SOX6 and confirming the expression of SOX6 in glioma.
Immunohistochemical analysis of SOX6 in glioma
Sectioned materials from formalin-fixed tumors were analysed using the antibody against SOX6 and MIB-1, which demonstrates the proliferative activity of cells. All 18 glioma tissues analysed expressed SOX6 in the nuclei of the tumor cells, but only a few SOX6-positive cells were detected in non-neoplastic tissue from the cerebral cortex ( Figure 6 and Table 2 ). The SOX6 expression and the histological malignancy and proliferation status of the gliomas as well as the seroreactivity against SOX6 are summarized in Table 2 . The SOX6 expression was confirmed in all tumor tissues from glioma patients whose sera reacted with SOX6. Although we evaluated the possibility of a relationship between the expression of SOX6 and proliferative activity in gliomas, no apparent correlation was shown, as determined by MIB-1 immunohistochemistry.
Discussion
Although brain tumors are essentially located in an immunologically privileged site, several glioma antigens have recently been isolated by SEREX. (Sahin et al., 1995; Fischer et al., 2001; Struss et al., 2001) However, these isolated antigens showed broad gene expression; thus, it is unclear how immune responses against these antigens could be induced in glioma patients or whether these immune responses are specific for glioma patients. Our study demonstrated that the presence of IgG antibodies against SOX6 in sera was specific for glioma patients. Moreover, the seroreactivity against SOX6 was observed in one-third of glioma patients. These IgG responses detected by SEREX were confirmed by Western blot and ELISA analyses.
A variety of mechanisms that may cause an immune response against tumor antigens have been discussed, Figure 6 Immunohistochemical analysis of SOX6 expression in gliomas and normal brain tissue. Only a few SOX6-positive cells were detected in non-neoplastic tissue from the cerebral cortex (a). In a diffuse astrocytoma (b, case OA4), an anaplastic astrocytoma (c, case AA1), and a glioblastoma (d, case GB4), SOX6 was expressed in the nucleus of most tumor cells. Scale bar ¼ 25 mm including overexpression, mutations, and post-translational modifications of the protein (Takahashi et al., 1995; Brass et al., 1997; Scanlan et al., 1998) . The present study revealed that the SOX6 expression was very weak in normal adult tissues except for the testis, which is an immunologically privileged anatomical site, but was highly expressed in gliomas. No mutation of the SOX6 gene was observed by sequence analysis. These results suggest that the selective, high expression of SOX6 in gliomas may cause the specific immune responses in glioma patients.
The SOX gene family is defined by the Sry-related HMG box domain that mediates sequence-specific DNA binding (Pevny & Lovell-Badge, 1997; Wegner, 1999) . The known functions of the SOX proteins during development are both diverse and complex: Sry has a well-described role in sex determination (Whitfield et al., 1993) , SOX1-3 in lens development (Kamachi et al., 1998) , SOX4 in endocardial ridge development in the heart and pro-B-cell expansion (Schilham et al., 1996) , SOX9 in chondrogenesis and sex determination (Wagner et al., 1994; Bi et al., 1999) , and SOX10 in neural crest cell differentiation (Pingault et al., 1998; Southard-Smith et al., 1998) . SOX6 has been suggested to regulate embryonic development and determine cell fate. Mouse SOX6 is expressed in the CNS during embryogenesis, but the expression significantly decreases in the adult CNS (Connor et al., 1995) . SOX6, SOX5, and SOX9 are expressed simultaneously and at high levels from early stages of chondrogenesis in all cartilagenous sites in mouse embryos (Lefebvre et al., 1998) . In this study, we showed that the human SOX6 was expressed in fetal brain and gliomas, but faintly in the adult brain. Developmentally regulated proteins in the CNS, such as Nestin (Almqvist et al., 2002) and Musashi (Toda et al., 2001) , have also been shown to be expressed in undifferentiated neural stem cells and glioma, but not in mature neurons. These results suggest that glioma may exhibit a gene expression pattern similar to that of the cells in the developing CNS.
Regarding whether aberrant expression of the SOX6 gene is related to tumorigenesis, no significant relationship was shown between the SOX6 expression and histological malignancy or proliferative activity, as determined by the MIB-1 index (Cattoretti et al., 1992) in gliomas ( Figure 1b and Table 2 ). This indicates that SOX6 may not promote proliferation. Ectopic expression of SOX3 was shown to cause oncogenic transformation of chicken embryo fibroblasts (Xia et al., 2000) . Thus, aberrant expression of SOX6 may induce transformation activity in the early stage of oncogenesis in gliomas. Further investigation is required to clarify the role of SOX6 in oncogenesis.
Two major size classes of SOX6 transcripts in mouse (Hagiwara et al., 2000) , rat (Narahara et al., 2002) , and human (Cohen-Barak et al., 2001) have been demonstrated: a small transcript of about 3 kb and a large one of 8-9 kb. The size difference is thought to be owing to the different sizes of the 3 0 and 5 0 UTRs (Lefebvre et al., 1998) . Alternate promoter usage or alternate RNA processing may underlie the differences in transcript sizes. In this study, Northern blot analysis showed that the large transcript of SOX6 was detected in human gliomas. However, immunoblot analysis revealed bands The seroreactivities of SOX6 are described as +, positive; À, negative. b The proliferating cell indexes were analysed in a total of more than 1000 tumor cells on more than three areas expressing the highest numbers of MIB-1-positive nuclei.
c The patterns of staining are described as À, negative or faint staining; +, positive in less than 30% of tumor cells; ++, positive in 30% to less than 70% of tumor cells; +++, positive in more than 70% of tumor cells. NA, not available; M, male; F, female of the same size, corresponding to SOX6, in gliomas and 293T cells that expressed the small SOX6 transcript. This was because, as shown in previous reports (Lefebvre et al., 1998) , both transcripts of the human SOX6 gene appear to encode the same protein.
However, the functional significance of the large and small transcripts is still unknown.
To evaluate tumor antigens for diagnostic and therapeutic purposes, accurate information on the protein expression pattern is essential. We examined SOX6 expression by Western blot and immunohistochemical analyses in glioma tissues and normal brain. High SOX6 expression was observed in all analysed gliomas; in contrast, no apparent expression was detected in the normal adult brain. Moreover, SOX6 expression was confirmed in all tumor tissues from patients whose sera contained IgG antibodies against SOX6 ( Table 2 ). The fact that a glioma antigen, SOX6, induces IgG responses in one-third of glioma patients implies the coexistence of cognate T-cell help. Indeed, several antigens including MAGE, tyrosinase, and NY-ESO-1 isolated by SEREX were originally identified by CTL responses (van der Bruggen et al., 1991; Brichard et al., 1993; Robbins et al., 1994) . The specific IgG responses against SOX6 are likely to be caused by its predominant expression in gliomas. These results suggest that SOX6 may be a target for the immunotherapy of glioma.
Materials and methods

Patients, sera, and tissues
This study was approved by the local ethical review board of Keio University (No. 12-21-2). Tumor tissues and patient sera were obtained from the Department of Neurosurgery, Keio University, School of Medicine. The tumors obtained from surgical cases were classified according to the recent World Health Organization (WHO) criteria (Kleihues et al., 2002) as follows: glioblastoma (WHO grade IV), anaplastic astrocytoma (WHO grade III), or diffuse astrocytoma (WHO grade II). The tissues were frozen in liquid nitrogen immediately after surgery and then stored at À801C.
Construction of the cDNA library
Total RNA of adult human testis was purchased from CLONTECH Laboratories, Inc. The poly(A) þ RNA was purified twice with latex beads coated with oligodeoxythymidylic acid (Oligotex-dT30 super; Takara Shuzo, Kyoto, Japan). The testis cDNA library was constructed with 5 mg of poly(A) þ RNA. First-strand synthesis was performed using an oligodeoxythymidylate primer with an internal XhoI site and 5-methyl-CTP. The cDNA was ligated to EcoRI adapters and digested with XhoI. The cDNA fragments were directionally inserted into the bacteriophage expression vector, lambda ZAP II (Stratagene, La Jolla, CA, USA), packaged into phage particles, resulting in 3 Â 10 6 primary recombinants in this library.
Immunoscreening of the testis cDNA library and characterization of immunoreactive clones
The serum from each glioma patient was diluted 1 : 100 in 5% skim milk in Tris-buffered saline with 0.05%. polyoxyethylenesorbitan monolaurate. The sera were preabsorbed with transformed E. coli lysates and E. coli infected with lambda ZAP phage. The four diluted sera were mixed, to a final dilution of 1 : 400 for each serum. The testis cDNA library was expressed in BL21 (DE3) pLysE, and the colonies were transferred to nitrocellulose membranes (Hybond-C; Amersham Pharmacia, Buckinghamshire, England). The membranes were incubated in the diluted sera for 4 h at room temperature, followed by 1 : 4000-diluted goat anti-human IgG (Fc) antibody conjugated with alkaline phosphatase (Cappel, Aurola, OH, USA). Nitro blue tetrazolium (Boehringer Mannheim, GmbH, Germany) and 5-bromo-4-chloro-3-indolyl phosphate (Sigma Chemical Co., St Louis, MO, USA) were used for the enzymatic detection of bound secondary antibodies. Positive plaques were picked from the plates and purified through secondary and tertiary rounds of additional screening. The purified cDNAs were amplified by PCR using the Ex Taq kit (Takara Shuzo) and sequenced using the Big Dye Terminator Cycle Sequencing Ready Reaction Kit and an ABI Prism automated sequencer (Perkin-Elmer, Branchburg, NJ, USA). The sequenced DNAs were analysed by a BLAST search of genetic databases at the National Center for Biotechnology Information.
Detection of antibodies against SOX6 by SEREX
Monoclonal phages from clones that reacted with the sera used for the immunoscreening were mixed with nonreactive phages of the cDNA library as internal negative controls at a ratio of 1 : 10 and used to transfect bacteria. IgG antibodies in the 1 : 100-diluted E. coli-preabsorbed sera from glioma patients, other patients, and healthy controls were tested with the above-described phage assay to determine antibody responses against SOX6.
Western blot analysis of patient sera against the HMG box of SOX6
The cDNA of the HMG box domain of SOX6 (SOX6-HMG) was subcloned into plasmid pET32a (Novagen), and the Histagged protein was expressed in E. coli strain BL21 (DE3) Lys S (Novagen). The recombinant SOX6-HMG was purified using a HiTrap Chelating affinity column (Amersham Pharmacia). The control recombinant protein (His-S) was made using the pET32a without the SOX6-HMG. The purified recombinant SOX6-HMG was mixed with an equal volume of sodium dodecyl sulfate (SDS)-sample buffer composed of 2% SDS, 10% b-mercaptoethanol, 10% glycerol, 1 mM EDTA, 40 mM Tris, and 240 mM glycine at pH 8.5 and boiled for 3 min. The same amount of total protein (10 mg) was loaded in each lane of SDS-polyacrylamide gels (10%). After electrophoresis, the gels were transferred to a nitrocellulose sheet (Hybond C þ ; Amersham Pharmacia) by electroblotting. After blocking with 5% skim milk for 2 h, the sheets were incubated with 1 : 100-diluted sera from the glioma patients for 1 h at room temperature. After washing, the blots were incubated with 1 : 2000-diluted goat anti-human IgG (Fc) antibody conjugated with alkaline phosphatase. This was followed by the enzymatic detection of the bound secondary antibodies.
ELISA of patient sera against SOX6-HMG overnight 96-well plates were coated with 100 ng/well of purified recombinant SOX6-HMG. Control wells were coated with the purified recombinant His-S protein made by the control pET32a plasmid. After washing and blocking the wells with 2% BSA/PBS, 100 ml of diluted human serum (1 : 100-1 : 50 000) was added and the wells were incubated for 2 h at room temperature. The wells were then washed and incubated for 1 h at room temperature with peroxidase-conjugated antibody to human IgG, then reacted with the TMB substrate (Dako). The reaction product was measured at an optical density of 450 nm.
RT-PCR and Northern blot analyses
Total RNAs from normal tissues were purchased from CLONTECH Laboratories, Inc. Total RNAs from glioma tissues were isolated using Trizol (Gibco BRL). The cDNA preparations used as templates in the RT-PCR reactions were synthesized by incubating total RNA template 5 mg, oligo(dT), and Avian myeloblastosis virus reverse transcriptase (Takara, Tokyo) in a total reaction volume of 200 ml at 421C. Primers were designed as follows: forward primer, 5 0 -GATGCCAT CAACTCCACAGC-3 0 ; reverse primer, 5 0 -GCTGCAGAGCC ATTCATTGC-3 0 ; and for b-actin, forward primer, 5 0 -GGCA CCCAGCACAATGAAG-3 0 ; reverse primer, 5 0 -GCCGATC CACACGGAGTACT-3 0 . PCR was performed with an initial denaturation at 941C for 10 min, followed by 30 cycles of amplification (denaturation at 941C for 1 min, annealing at 601C for 1 min, and primer extension for 1 min at 721C), followed by a 6-min extension at 721C. Amplification products were analysed by agarose-gel electrophoresis and visualized by ethidium bromide staining.
Quantitative RT-PCR analysis was performed with a fluorescent dye, SYBR Green, using the ABI prism 7700 Sequence Detection System (Perkin-Elmer, Foster City, CA, USA) as described (Fink et al., 1998) . The thermal cycler parameters were: 10 min at 951C, and 50 cycles of denaturation at 951C for 30 s, annealing at 601C for 1 min, and extension at 721C for 1 min. The relative SOX6 expression level for each glioma tissue was normalized to the b-actin in each tissue, and calculated as the threshold cycle (C T ) value in each sample divided by the C T value in the normal brain. The C T value is defined as the value obtained in the PCR cycle when the fluorescence signal increases above the background threshold.
For Northern blot analysis, 10 mg of total RNA was fractionated by electrophoresis in a 1% formaldehyde agarose gel and transferred to a nylon membrane (Hybond-XL; Amersham Pharmacia). Radioisotope-labeled human SOX6 cDNA fragments (nucleotides 2250-2479) were prepared using the High Prime DNA Labeling Kit (Boehringer Mannheim). Prehybridization was performed at 651C for 30 min using Quick Hyb solution (Stratagene) and hybridization with the probes was performed overnight at 651C. The membranes were washed twice for 15 min with 2 Â SSC (trisodium citrate dihydrate) in 0.1% SDS at room temperature, followed by an additional wash for 30 min in 0.1 Â SSC and 0.1% SDS at 601C. Radioactive signals were detected using a BAS 5000 (Bio-Rad, Hercules, CA, USA).
Western blot analysis of SOX6 in gliomas SOX6 expression in glioma and normal brain was tested by Western blot analysis. SOX6 protein exists in the nuclei of mammalian cells (Yamashita et al., 2000) . To isolate nuclear extracts, normal brain tissue (purchased from CLONTECH Laboratories, Inc.), glioma tissues, and 293T cells transfected with the full-length short form of SOX6 cDNA (Cohen-Barak et al., 2001) were homogenized in 0.25 M sucrose and centrifuged for 10 min. Pellets were resuspended in 0.25 M sucrose supplemented with a protease inhibitor cocktail (Sigma Aldrich). Total protein (20 mg) were loaded on each lane, and the proteins were transferred onto a nitrocellulose membrane. The first antibody used was a rabbit anti-human SOX6 polyclonal antibody (10 mg/ml, CHEMICON International, Inc.), followed by 1 : 2000-diluted goat anti-rabbit IgG (Fc) antibody conjugated with alkaline phosphatase (Cappel, Aurora, OH, USA). To evaluate the specificity of the anti-SOX6 antibody, the antibody was incubated with 293T cells expressing SOX6 at a final concentration of 10 mg/ml in 1% PBS, then applied to a Western blot as described above.
Immunohistochemical staining
Paraffin-embedded tissue Sections (5 mm) were deparaffinized in xylene and rehydrated. The sections were treated with a heat-based antigen retrieval method, using a citrate solution (pH 6.0, 10 mM). Endogenous peroxidase was blocked by incubation in 0.3% hydrogen peroxide in methanol, and nonspecific binding of antibodies was blocked by incubation in 5% BSA (bovine serum albumin) in 0.02 M PBS and 0.1% Triton X-100 in PBS for 1 h. The slides were then incubated with anti-human SOX6 antibody (1 mg/ml) diluted in the same blocking solution overnight at 41C. The slides were incubated with second antibody (Universal Immuno-peroxidase Polymer, Anti-Rabbit; Histofine Simple Stain MAX PO (R), Nichirei Corporation, Japan) for 30 min at 371C, and the HRP labeling was visualized using DAB. The sections were lightly counterstained with hematoxylin. Each step was followed by three washes in PBS.
To evaluate the proliferative activity of the tumors, sections were stained with the monoclonal antibody MIB-1 that recognized the Ki-67 protein (Cattoretti et al., 1992) . Dewaxed and rehydrated sections in a 10-mM citrate buffer, pH 7, were processed five times for 4 min in a microwave oven at 600 W. After blocking with 5% BSA containing 3% horse serum in PBS, the sections were incubated with MIB-1 (1 : 50 dilution, Immunotech, Marseilles, France) overnight at 41C. After the second antibody reaction, sections were visualized by the avidin-biotin complex technique with DAB. The proliferating cell indexes were analysed for a total of more than 1000 tumor cells on more than three areas expressing the highest numbers of immunopositive nuclei. The analysis was made using a computer-assisted image analyser (Luzex F, Nireco, Japan).
